Bicycle Therapeutics plc: Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

-Continued clinical progress across pipeline including BT5528 end of Phase I dose escalation update; completion of enrollment in BT5528 initial dose expansion cohorts expected in Q4 BT8009 clinical

Related Keywords

United Kingdom ,Cambridge ,Cambridgeshire ,David Borah ,Genentech Immuno ,Sarah Sutton ,Kevin Lee ,Exchange Commission ,Genentech ,Nasdaq ,Chief Executive Officer ,Top Line Dose Escalation Results ,Phasei Trial ,Bicycle Toxin Conjugate ,Initial Cohorts ,Initial Expansion Cohorts ,Complete This ,Publications Highlighting Preclinical Data ,Molecular Cancer Therapeutics ,Molecular Cancer ,Medicinal Chemistry ,Genentech Immuno Oncology ,Cancer Research United Kingdom Centre ,Private Securities Litigation Reform Act ,Quarterly Report ,Consolidated Statements ,Capital Markets Investor Relations ,Bicycle ,Herapeutics ,Reports ,Third ,Quarter ,022 ,Financial ,Results ,Rovides ,Corporate ,Update ,